Proteon Therapeutics (PRTO) Reports Q2 Loss of $0.31/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Proteon Therapeutics Announces Second Quarter 2015 Financial Results
August 13, 2015 5:15 PM EDTWALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2015, and recent business highlights.
"I am pleased that the first Phase 3 clinical study of vonapanitase is on track to complete enrollment by the end of the year and that we recently enrolled our first patient in our second Phase 3 clinical study of vonapanitase," said Timothy Noyes, President and Chief Executive Officer of Proteon.
... More
Proteon Therapeutics Announces Second Quarter 2015 Financial Results
August 13, 2015 5:15 PM EDTWALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the quarter ended June 30, 2015, and recent business highlights.
"I am pleased that the first Phase 3 clinical study of vonapanitase is on track to complete enrollment by the end of the year and that we recently enrolled our first patient in our second Phase 3 clinical study of vonapanitase," said Timothy Noyes, President and Chief Executive Officer of Proteon.
... More
